BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16940419)

  • 21. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.
    Bouscary D; Chen YL; Guesnu M; Picard F; Viguier F; Lacombe C; Dreyfus F; Fontenay-Roupie M
    Exp Hematol; 2000 Jul; 28(7):784-91. PubMed ID: 10907640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
    Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
    J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.
    Pang WW; Pluvinage JV; Price EA; Sridhar K; Arber DA; Greenberg PL; Schrier SL; Park CY; Weissman IL
    Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3011-6. PubMed ID: 23388639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
    Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V
    Clin Cancer Res; 2012 Jun; 18(11):3079-89. PubMed ID: 22496271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
    Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
    Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
    Tauro S; Hepburn MD; Bowen DT; Pippard MJ
    Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors.
    Backx B; Broeders L; Touw I; Löwenberg B
    Leukemia; 1993 Jan; 7(1):75-9. PubMed ID: 8418382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia.
    Geest CR; Buitenhuis M; Vellenga E; Coffer PJ
    Haematologica; 2009 Aug; 94(8):1075-84. PubMed ID: 19644139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
    Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
    Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD.
    Claessens YE; Park S; Dubart-Kupperschmitt A; Mariot V; Garrido C; Chrétien S; Dreyfus F; Lacombe C; Mayeux P; Fontenay M
    Blood; 2005 May; 105(10):4035-42. PubMed ID: 15677568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
    Bhagat TD; Zhou L; Sokol L; Kessel R; Caceres G; Gundabolu K; Tamari R; Gordon S; Mantzaris I; Jodlowski T; Yu Y; Jing X; Polineni R; Bhatia K; Pellagatti A; Boultwood J; Kambhampati S; Steidl U; Stein C; Ju W; Liu G; Kenny P; List A; Bitzer M; Verma A
    Blood; 2013 Apr; 121(15):2875-81. PubMed ID: 23390194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quercetin induces autophagy in myelodysplastic bone marrow including hematopoietic stem/progenitor compartment.
    Daw S; Law S
    Environ Toxicol; 2021 Feb; 36(2):149-167. PubMed ID: 32902906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced growth of myelodysplastic colonies in hypoxic conditions.
    Thompson JE; Conlon JP; Yang X; Sanchez PV; Carroll M
    Exp Hematol; 2007 Jan; 35(1):21-31. PubMed ID: 17198870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.
    Tehranchi R; Fadeel B; Forsblom AM; Christensson B; Samuelsson J; Zhivotovsky B; Hellstrom-Lindberg E
    Blood; 2003 Feb; 101(3):1080-6. PubMed ID: 12393561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.